FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

High-dose recombinant influenza vaccine elicits stronger immune responses against A(H3N2) than standard-dose vaccines in healthy young adults.

The US Food and Drug Administration is moving to speed drug development and review by launching real-time clinical trials.

The FDA accepted an NDA for a bictegravir and lenacapavir single-tablet regimen for adults with HIV-1 who have achieved virologic suppression.

For children treated for suspected septic shock, outcomes were similar in fluid resuscitation with balanced crystalloid fluid vs 0.9% saline.

Physical activity-based interventions may help reduce chronic postsurgical pain, but current evidence is inconclusive.

Florida’s KidCare expansion has been mired in lawsuits and ongoing negotiations between the state and federal regulators.

For patients with early infection with Lyme disease, standard and modified 2-tiered testing diagnostic algorithms have low sensitivity.

A new proposal could make it easier for patients to access breakthrough medical devices through Medicare insurance.

During a congressional hearing, HHS Secretary Robert F Kennedy Jr declined to say whether he would follow vaccine recommendations from the latest CDC nominee.

Phase 3 ReSPECT trial data show rezafungin is noninferior to standard antimicrobial regimens for the prophylaxis of invasive ...

Participation in state AIDS Drug Assistance Programs was associated with improved HIV treatment outcomes and high rates of viral suppression.